Analysis of long-term safety and efficacy of risankizumab in patients with moderate-to-severe Crohn’s Disease: 3-year results from the SEQUENCE study
Zeitschrift für Gastroenterologie · 01.08.2026 · 64 (08) · e326-e327
DOI: 10.1055/s-0046-1826527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.08.2026. Verfasst von L Peyrin-Biroulet und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Part 2 of the ongoing SEQUENCE study examines the long-term efficacy and safety of risankizumab (RZB), an interleukin-23 p19 inhibitor, in patients (pts) with moderate-to-severe Crohn’s disease (CD). Here, we report the 3-year (yr) results from the SEQUENCE study.
Methods
In Part 2 of SEQUENCE (NCT04524611), pts randomised to RZB who completed the Part 1 week (wk) 48 visit continued on open-label 360mg subcutaneous (SC) RZB every 8 wks (Q8w). 1 Clinical remission (per CD activity index [CDAI] and per stool frequency [SF]/abdominal pain score [APS]), steroid-free clinical remission, endoscopic response, endoscopic remission, steroid-free endoscopic remission, deep remission, mucosal healing, Inflammatory Bowel Disease Questionnaire (IBDQ) remission, and normalisation of high-sensitivity C-reactive protein (hs-CRP) and faecal calprotectin (FCP) levels were assessed through wk 148. Inadequate responders could receive≤2 rescue treatments (600 mg RZB intravenous dose followed by 360 mg SC Q8W),≥16 weeks apart. 1 All intent-to-treat (ITT) pts were assessed as observed (AO) and using modified nonresponder imputation (mNRI). Data before receiving rescue treatment are presented. Treatment emergent adverse events (TEAEs) reported on or after the first RZB dose in Part 2 were analysed (cutoff date: 02JUL2025).
Results
In total, 224 ITT pts entered Part 2. Compared to wk 52, data AO showed similar or higher rates of clinical remission at wk 148 (CDAI: 76.4% vs 86.3%; SF/APS: 72.1% vs 75.9%), steroid-free clinical remission (CDAI: 75.9% vs 83.5%; SF/APS: 72.1% vs 73.0%), IBDQ remission (62.1% vs 69.0%), endoscopic response (55.8% vs 65.1%), endoscopic remission (39.2% vs 48.8%), steroid-free endoscopic remission (38.7% vs 48.3%), mucosal healing (37.3% vs 43.6%), and deep remission (31.5% vs 36.8%) ([ Fig. 1 ]). Also, compared to wk 52, a greater proportion of pts with elevated biomarker levels at baseline had normalised levels at wk 148 (hs-CRP: 53.1% vs 69.4%; FCP: 56.9% vs 66.3%). Lower efficacy rates were observed per mNRI but also showed sustained efficacy through wk 148. The profiles of TEAEs and TEAEs of special interest were consistent with the known safety profile of RZB ([ Fig. 2 ]). 2,3 No deaths occurred during Part 2. Fig. 1 Fig. 2 Conclusion : 3-yrs of continuous RZB therapy in SEQUENCE resulted in durable long-term clinical, endoscopic, and quality of life benefits. The safety profile is consistent with the known safety profile and supports long-term RZB treatment ([ Fig. 3 ]). Fig. 3 Informationen zum Einsatz von KI : Encore Publication History Article published online: 27 August 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Zitieren
APA
Peyrin-Biroulet, L., Atreya, R., Danese, S., Lindsay, J. O., Chapman, J. C., Anschutz, T., Huang, X., Zambrano, J., Aponte, F., Joshi, N., Schreiber, S., & Cross, R. K. (2026). Analysis of long-term safety and efficacy of risankizumab in patients with moderate-to-severe Crohn’s Disease: 3-year results from the SEQUENCE study. Zeitschrift für Gastroenterologie, 64(08), e326-e327. https://doi.org/10.1055/s-0046-1826527
Vancouver
Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, et al. Analysis of long-term safety and efficacy of risankizumab in patients with moderate-to-severe Crohn’s Disease: 3-year results from the SEQUENCE study. Zeitschrift für Gastroenterologie. 2026;64(08):e326-e327. doi:10.1055/s-0046-1826527
BibTeX
@article{PeyrinBiroulet2026,
author = {Peyrin-Biroulet, L and Atreya, R and Danese, S and Lindsay, J O and Chapman, J C and Anschutz, T and Huang, X and Zambrano, J and Aponte, F and Joshi, N and Schreiber, S and Cross, R K},
title = {Analysis of long-term safety and efficacy of risankizumab in patients with moderate-to-severe Crohn’s Disease: 3-year results from the SEQUENCE study},
journal = {Zeitschrift für Gastroenterologie},
year = {2026},
volume = {64},
number = {08},
pages = {e326--e327},
doi = {10.1055/s-0046-1826527}
}
EUVIMED